Blurbs

Analysts Are Bullish on These Healthcare Stocks: CymaBay Therapeutics (CBAY), Aslan Pharmaceuticals (ASLN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CymaBay Therapeutics (CBAYResearch Report), Aslan Pharmaceuticals (ASLNResearch Report) and Praxis Precision Medicines (PRAXResearch Report) with bullish sentiments.

CymaBay Therapeutics (CBAY)

JonesTrading analyst Sean Kim PhD reiterated a Buy rating on CymaBay Therapeutics today and set a price target of $8.00. The company’s shares closed last Wednesday at $3.53.

According to TipRanks.com, PhD is a 2-star analyst with an average return of 3.0% and a 37.5% success rate. PhD covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Phathom Pharmaceuticals, and Satsuma Pharmaceuticals.

CymaBay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $10.00.

See the top stocks recommended by analysts >>

Aslan Pharmaceuticals (ASLN)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals, with a price target of $7.00. The company’s shares closed last Wednesday at $0.76, close to its 52-week low of $0.36.

According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.4% and a 30.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Stealth Biotherapeutics.

Aslan Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.

Praxis Precision Medicines (PRAX)

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Praxis Precision Medicines, with a price target of $10.00. The company’s shares closed last Wednesday at $3.17, close to its 52-week low of $1.63.

According to TipRanks.com, Tsao is a 3-star analyst with an average return of 2.4% and a 40.3% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Crinetics Pharmaceuticals, and Apellis Pharmaceuticals.

Currently, the analyst consensus on Praxis Precision Medicines is a Moderate Buy with an average price target of $4.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CBAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos